ProShare Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.12M | Buy |
8,514
+120
| +1% | +$15.9K | ﹤0.01% | 767 |
|
|
2025
Q4 | $1.19M | Buy |
8,394
+643
| +8% | +$93.2K | ﹤0.01% | 782 |
|
|
2025
Q3 | $1.09M | Sell |
7,751
-332
| -4% | -$45K | ﹤0.01% | 787 |
|
|
2025
Q2 | $1.02M | Sell |
8,083
-662
| -8% | -$75.9K | ﹤0.01% | 815 |
|
|
2025
Q1 | $967K | Sell |
8,745
-787
| -8% | -$99.7K | ﹤0.01% | 826 |
|
|
2024
Q4 | $1.3M | Sell |
9,532
-11,206
| -54% | -$1.39M | ﹤0.01% | 818 |
|
|
2024
Q3 | $2.39M | Buy |
20,738
+9,780
| +89% | +$1.34M | 0.01% | 653 |
|
|
2024
Q2 | $1.51M | Sell |
10,958
-871
| -7% | -$119K | ﹤0.01% | 701 |
|
|
2024
Q1 | $1.63M | Buy |
11,829
+383
| +3% | +$52.3K | ﹤0.01% | 695 |
|
|
2023
Q4 | $1.51M | Sell |
11,446
-212
| -2% | -$24.4K | ﹤0.01% | 691 |
|
|
2023
Q3 | $1.31M | Sell |
11,658
-355
| -3% | -$37.4K | ﹤0.01% | 688 |
|
|
2023
Q2 | $1.13M | Sell |
12,013
-429
| -3% | -$41.9K | ﹤0.01% | 707 |
|
|
2023
Q1 | $1.26M | Sell |
12,442
-2,889
| -19% | -$301K | ﹤0.01% | 699 |
|
|
2022
Q4 | $1.83M | Buy |
15,331
+535
| +4% | +$62.7K | 0.01% | 633 |
|
|
2022
Q3 | $1.57M | Buy |
14,796
+534
| +4% | +$54.2K | 0.01% | 657 |
|
|
2022
Q2 | $1.39M | Sell |
14,262
-5,034
| -26% | -$465K | ﹤0.01% | 705 |
|
|
2022
Q1 | $1.81M | Sell |
19,296
-5,006
| -21% | -$424K | ﹤0.01% | 741 |
|
|
2021
Q4 | $2.07M | Sell |
24,302
-4,698
| -16% | -$432K | ﹤0.01% | 751 |
|
|
2021
Q3 | $2.78M | Buy |
29,000
+1,452
| +5% | +$137K | 0.01% | 645 |
|
|
2021
Q2 | $2.68M | Buy |
27,548
+5,559
| +25% | +$533K | 0.01% | 661 |
|
|
2021
Q1 | $2.14M | Buy |
21,989
+5,893
| +37% | +$618K | 0.01% | 681 |
|
|
2020
Q4 | $1.54M | Sell |
16,096
-543
| -3% | -$52.4K | 0.01% | 713 |
|
|
2020
Q3 | $1.6M | Buy |
16,639
+302
| +2% | +$34.9K | 0.01% | 616 |
|
|
2020
Q2 | $1.99M | Buy |
16,337
+1,978
| +14% | +$219K | 0.01% | 560 |
|
|
2020
Q1 | $1.24M | Sell |
14,359
-7,756
| -35% | -$759K | 0.01% | 560 |
|
|
2019
Q4 | $2.38M | Sell |
22,115
-4,827
| -18% | -$505K | 0.01% | 579 |
|
|
2019
Q3 | $2.43M | Sell |
26,942
-1,920
| -7% | -$179K | 0.01% | 554 |
|
|
2019
Q2 | $2.44M | Sell |
28,862
-5,638
| -16% | -$463K | 0.01% | 550 |
|
|
2019
Q1 | $3.04M | Buy |
34,500
+1,099
| +3% | +$91.9K | 0.02% | 518 |
|
|
2018
Q4 | $2.38M | Sell |
33,401
-6,684
| -17% | -$640K | 0.02% | 537 |
|
|
2018
Q3 | $4.93M | Buy |
40,085
+165
| +0.4% | +$18.7K | 0.03% | 422 |
|
|
2018
Q2 | $3.92M | Sell |
39,920
-3,626
| -8% | -$325K | 0.03% | 491 |
|
|
2018
Q1 | $3.61M | Sell |
43,546
-6,518
| -13% | -$550K | 0.02% | 506 |
|
|
2017
Q4 | $3.88M | Sell |
50,064
-1,726
| -3% | -$118K | 0.03% | 479 |
|
|
2017
Q3 | $3.17M | Buy |
51,790
+4,737
| +10% | +$250K | 0.03% | 468 |
|
|
2017
Q2 | $2.16M | Sell |
47,053
-943
| -2% | -$45.7K | 0.02% | 532 |
|
|
2017
Q1 | $2.08M | Sell |
47,996
-10,638
| -18% | -$456K | 0.02% | 546 |
|
|
2016
Q4 | $2.27M | Buy |
58,634
+1,536
| +3% | +$69.5K | 0.03% | 512 |
|
|
2016
Q3 | $2.89M | Sell |
57,098
-10,048
| -15% | -$500K | 0.04% | 391 |
|
|
2016
Q2 | $3.05M | Sell |
67,146
-9,021
| -12% | -$415K | 0.04% | 351 |
|
|
2016
Q1 | $3.01M | Sell |
76,167
-8,552
| -10% | -$339K | 0.04% | 339 |
|
|
2015
Q4 | $4.79M | Buy |
84,719
+8,191
| +11% | +$416K | 0.06% | 296 |
|
|
2015
Q3 | $3.04M | Sell |
76,528
-2,501
| -3% | -$121K | 0.04% | 362 |
|
|
2015
Q2 | $3.77M | Sell |
79,029
-5,936
| -7% | -$252K | 0.05% | 340 |
|
|
2015
Q1 | $3.37M | Buy |
84,965
+18,338
| +28% | +$656K | 0.04% | 405 |
|
|
2014
Q4 | $1.49M | Sell |
66,627
-2,629
| -4% | -$49.8K | 0.02% | 663 |
|
|
2014
Q3 | $1.08M | Sell |
69,256
-13,771
| -17% | -$206K | 0.01% | 1046 |
|
|
2014
Q2 | $1.23M | Sell |
83,027
-42,232
| -34% | -$596K | 0.02% | 1061 |
|
|
2014
Q1 | $2.02M | Buy |
125,259
+90,732
| +263% | +$1.55M | 0.03% | 745 |
|
|
2013
Q4 | $322K | Sell |
34,527
-31,180
| -47% | -$304K | ﹤0.01% | 1136 |
|
|
2013
Q3 | $744K | Buy |
65,707
+9,823
| +18% | +$135K | 0.02% | 1111 |
|
|
2013
Q2 | $748K | Buy |
+55,884
| New | +$687K | 0.01% | 1028 |
|
Other funds holding NBIX
VPM
VCM
ProShare Advisors's NBIX Position: Q1 2026 in Review
ProShare Advisors increased its Neurocrine Biosciences (NBIX) stake by 1.4% in Q1 2026, buying an estimated $15.9K and bringing the position to 8,514 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #767.
ProShare Advisors first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.93M in Q3 2018. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- ProShare Advisors held 8,514 shares of Neurocrine Biosciences worth $1.12M as of Q1 2026.
- ProShare Advisors bought 120 Neurocrine Biosciences shares in Q1 2026, an estimated $15.9K.
- Neurocrine Biosciences made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #767 holding.
- ProShare Advisors first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- ProShare Advisors's Neurocrine Biosciences position peaked at $4.93M in Q3 2018.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.